Innovative mucosal vaccine formulations against influenza A virus infections
- 1Institut National de la Recherche Agronomique (INRA), France
- 2INRA Centre Jouy-en-Josas, France
Despite efforts made to develop efficient preventive strategies, influenza A virus (IAV) infections continue to cause serious clinical and economic problems. Current licensed human vaccines are mainly inactivated whole virus particles or split-virion administrated via the parenteral route. These vaccines provide incomplete protection against IAV in high-risk groups and are poorly/not effective faced with constant antigenic drift/shift occurring in circulating strains. Advances in mucosal vaccinology and in the understanding of the protective anti-influenza immune mechanisms suggest that intranasal immunization is a promising strategy to fight against IAV. To date, human mucosal anti-influenza vaccines consist of live attenuated strains administrated intranasally, which elicit higher local humoral and cellular immune responses than conventional parenteral vaccines. However, because of inconsistent protective efficacy and safety concerns regarding the use of live viral strains, new vaccine candidates are urgently needed. To prime and induce potent and long-lived protective immune responses, mucosal vaccine formulations need to ensure the immunoavailability and the immunostimulating capacity of the vaccine antigen(s) at the mucosal surfaces, while being minimally reactogenic/toxic. The purpose of this review is to compile innovative delivery/adjuvant systems tested for intranasal administration of inactivated influenza vaccines, including micro/nanosized particulate carriers such as lipid-based particles, virus-like particles and polymers associated or not with immunopotentiatory molecules including microorganism-derived toxins, Toll-like receptor ligands and cytokines. The capacity of these vaccines to trigger specific mucosal and systemic humoral and cellular responses against IAV and their (cross)-protective potential are considered.
Keywords: Influenza A virus, Mucosal vaccine, adjuvant, delivery system, Intranasal immunisation
Received: 15 Jan 2019;
Accepted: 27 Jun 2019.
Edited by:Fabio Bagnoli, GlaxoSmithKline (Italy), Italy
Reviewed by:Arun Kumar, Coalition for Epidemic Preparedness Innovations (CEPI), Norway
Randy A. Albrecht, Icahn School of Medicine at Mount Sinai, United States
Copyright: © 2019 Chevalier and Calzas. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Dr. Christophe Chevalier, Institut National de la Recherche Agronomique (INRA), Paris, France, email@example.com
Dr. Cynthia Calzas, INRA Centre Jouy-en-Josas, Jouy-en-Josas, 78352, Île-de-France, France, firstname.lastname@example.org